Rangering i aksjer
#33655
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Aksjekurs
$0.07591393
Sist synkronisert: 2026-08-14
Handel TME Pharma N.V. (ALTME)
Pris ALTME pris med markedsverdi på B
Markedsverdi av TME Pharma N.V.(ALTME)
Markedsverdi: $7.15M
Per August 2026 har TME Pharma N.V. en markedsverdi på $7.15M. Dette gjør TME Pharma N.V. til det 33655th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for TME Pharma N.V. fra 2016 til 2026
ALTME sammenlignet med topp 5 mest populære stocks
| Pris på ALTME |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+76,244,200.20%
|
|
|
|
|
$4.490T
|
+62,792,774.37%
|
|
|
|
|
$4.162T
|
+58,211,108.67%
|
|
|
|
|
$3.676T
|
+51,413,501.77%
|
|
|
|
|
$2.833T
|
+39,619,964.72%
|
